| Literature DB >> 20222796 |
David T MacLaughlin1, Patricia K Donahoe.
Abstract
According to the 2008 American Cancer Society statistics, cancer remains the second leading cause of death in American today. Early detection, innovative surgery, new drugs and increased public education regarding avoidable risk factors, such as smoking, have had significant impact on the incidence and survival rates of many cancers, while overall death rates from all cancers have declined a modest 5% over the past 50 years. Ovarian cancer statistics, however, have not been as encouraging. Despite recent advances in the management of this disease, 5-year survival has not improved, and the search continues for rationally designed new treatments. Müllerian Inhibiting Substance is a strong candidate because it addresses many of the deficiencies of existing treatments. Namely, Müllerian Inhibiting Substance has little demonstrated toxicity, it complements the activity of known anticancer drugs, it is highly specific against cancers expressing its receptor and it inhibits the proliferation of drug-resistant tumors.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20222796 PMCID: PMC3935316 DOI: 10.2217/fon.09.172
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404